Werfen Academy Corner– news and updates

Dear Werfen Partners and Colleagues,

Welcome back to the Werfen Academy corner, your go-to source for milestones, platform growth, and regional highlights across our global e‑Learning network.

Today, we’re excited to celebrate a major landmark: EEMEA has surpassed 4,000 learners. As of February 2026, Werfen Academy in fact counts 4,055 registered users, up from 3,399 in February 2025 (+656 year over year). This sustained growth reflects our shared commitment to continuous learning and professional development.

WA 2026

Throughout 2025, KSA has consistently led the region, representing nearly 40% of the total user base. Poland and Romania have maintained their strong positions in second and third place, respectively, reinforcing their steady engagement over the year.

WA 2026 2

Exciting News! Two NEW Categories Now Available on Werfen Academy

This year, as we celebrate the 5th anniversary of the official kick-off of our activities in EEMEA, we are glad to introduce two new categories on our e‑Learning platform: Transfusion and Transplant. 

To mark this important moment, all new activities in these categories will be freely accessible to all our customers throughout 2026. The expanded offering will now feature Transfusion courses on Immunohematology, Genotyping and Alloimmunization, as well as Transplant courses covering General HLA Concepts, HLA Antibody Testing and Crossmatching, and Stem Cell Transplantation. Together, this new content will enrich our portfolio with even more expert, high‑quality learning content.

This Issue’s Featured NEW Courses

  • HEMOSTASIS: “Bridging the Gap: Lab Testing Strategies for Transitioning Patients from Direct Oral Anticoagulants to Unfractionated Heparin” (HEW88) is a Werfen presentation at the 2025 ISTH Congress by Deepa J. Arachchillage. This talk illustrates UFH’s mechanism and monitoring limitations, comparing APTT with the anti‑Xa assay. It also highlights DOAC interference with heparin monitoring and how solutions like DOAC‑Stop may overcome this. In concluding her presentation, Dr. Arachchillage introduces a practical risk‑based algorithm for safe UFH initiation.
  • ACUTE CARE: “Enhancing Patient Safety: Addressing the Potentially Fatal Consequences of Undetected Hemolysis at the Point of Care” (ACW54) is a Werfen presentation from ADLM 2025 featuring Robert Cooper, Nam Tran, and Alan Wu. This session underlines how undetected hemolysis skews potassium results in POC blood gas testing, risking misdiagnosis and mistreatment. Emerging technologies like the GEM 7000 can detect hemolysis in whole blood, improving accuracy, preventing delays, and strengthening patient safety.
  • AUTOIMMUNITY: The webinar “APS Testing in 2026: Updates in Criteria, Guidelines, Technologies, and Novel Biomarkers” (AIW38), led by Savino Sciascia, reviews the updated 2023 ACR/EULAR classification criteria and how they differ from diagnostic use in clinical practice. Dr. Sciascia discusses the challenges in applying the criteria—especially in pregnancy morbidity—and highlights the importance of risk stratification. Emerging biomarkers, such as anti‑β2GP1 domain 1 and aPS/PT, may offer improved diagnostic and prognostic insight.

Thank you for your continued commitment and excellent work. Let’s continue to leverage Werfen Academy to drive an even greater impact in 2026!

Werfen Academy Team 

Last modified on Thursday, 04 June 2026 14:55

 

All rights reserved. © werfen.com

Get in touch

with the EEMEA team:

eemea@werfen.com

 

werfenplain

Issues

Go to top